These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 39266679)

  • 1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Knudsen LA; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
    Oncogene; 2024 Oct; 43(43):3197-3213. PubMed ID: 39266679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
    bioRxiv; 2024 May; ():. PubMed ID: 38766099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
    Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
    Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
    Jin L; Garcia J; Chan E; de la Cruz C; Segal E; Merchant M; Kharbanda S; Raisner R; Haverty PM; Modrusan Z; Ly J; Choo E; Kaufman S; Beresini MH; Romero FA; Magnuson S; Gascoigne KE
    Cancer Res; 2017 Oct; 77(20):5564-5575. PubMed ID: 28819026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
    Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
    Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
    Heemers HV; Schmidt LJ; Kidd E; Raclaw KA; Regan KM; Tindall DJ
    Prostate; 2010 Jun; 70(9):959-70. PubMed ID: 20166126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
    Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
    Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
    Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
    Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.
    Culig Z
    J Cell Physiol; 2016 Feb; 231(2):270-4. PubMed ID: 26201947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-4 activates androgen receptor through CBP/p300.
    Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
    Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
    Xu S; Fan L; Jeon HY; Zhang F; Cui X; Mickle MB; Peng G; Hussain A; Fazli L; Gleave ME; Dong X; Qi J
    Cancer Res; 2020 Aug; 80(15):3074-3087. PubMed ID: 32522824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy.
    Zhang D; Ma B; Liu D; Wu W; Zhou T; Gao Y; Yang C; Jian Y; Fan Y; Qian Y; Ma J; Gao Y; Chen Y; Xu S; Li L
    EBioMedicine; 2024 Jul; 105():105212. PubMed ID: 38954976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells.
    Gong AY; Eischeid AN; Xiao J; Zhao J; Chen D; Wang ZY; Young CY; Chen XM
    BMC Cancer; 2012 Oct; 12():492. PubMed ID: 23095762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 16. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
    PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells.
    Ianculescu I; Wu DY; Siegmund KD; Stallcup MR
    J Biol Chem; 2012 Feb; 287(6):4000-13. PubMed ID: 22174411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer.
    Pimenta R; Camargo JA; Candido P; Ghazarian V; Gonçalves GL; Guimarães VR; Romão P; Chiovatto C; Mioshi CM; Dos Santos GA; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Viana NI; Reis ST
    Cell Physiol Biochem; 2022 Dec; 56(S4):1-15. PubMed ID: 36458578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.